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The magnitude of the problem
Diverticular disease of the colon (DDC) is one of 
the most common gastrointestinal disorders, 
involving a substantial burden on the health sys-
tem in direct and indirect costs and a marked 
deterioration in quality of life for patients. DDC 
includes a number of conditions, ranging from 
asymptomatic diverticular disease to complicated 
acute diverticulitis (AD).1 Because it is often asymp-
tomatic and may never be identified, the true inci-
dence and prevalence of DDC is still not accurately 
established, although it is now widely accepted that 
the global incidence of both uncomplicated and 
complicated DDC is increasing. In recent years, 
several studies have assessed the economic impact 
of this disease. In the year 2000, the total (direct 
and indirect) cost of diverticular disease was esti-
mated to surpass $2.6 billion in the USA.2 In a 
follow-up study, the total cost for 2004 had 
increased to more than $4.0 billion.3 Moreover, 
related physician visits in the USA grew from 2.2 
million in 1998 to almost 2.7 million in 2009, 
while hospital stays increased from 230,000 to 
over 283,000 within the same period.2,4 Data 
from the UK also show an increase, from 49,000 
Progress and challenges in the management 
of diverticular disease: which treatment?
Angel Lanas, Daniel Abad-Baroja and Aitor Lanas-Gimeno
Abstract: Diverticular disease of the colon (DDC) includes a spectrum of conditions from 
asymptomatic diverticulosis to symptomatic uncomplicated diverticulosis, segmental colitis 
associated with diverticulosis, and acute diverticulitis without or with complications that may 
have serious consequences. Clinical and scientific interest in DDC is increasing because 
of the rising incidence of all conditions within the DDC spectrum, a better, although still 
limited understanding of the pathogenic mechanisms involved; the increasing socioeconomic 
burden; and the new therapeutic options being tested. The goals of treatment in DDC are 
symptom and inflammation relief and preventing disease progression or recurrence. The 
basis for preventing disease progression remains a high-fiber diet and physical exercise, 
although evidence is poor. Other current strategies do not meet expectations or lack a solid 
mechanistic foundation; these strategies include modulation of gut microbiota or dysbiosis 
with rifaximin or probiotics, or using mesalazine for low-grade inflammation in uncomplicated 
symptomatic diverticulosis. Most acute diverticulitis is uncomplicated, and the trend is to 
avoid hospitalization and unnecessary antibiotic therapy, but patients with comorbidities, 
sepsis, or immunodeficiency should receive broad spectrum and appropriate antibiotics. 
Complicated acute diverticulitis may require interventional radiology or surgery, although the 
best surgical approach (open versus laparoscopic) remains a matter of discussion. Prevention 
of acute diverticulitis recurrence remains undefined, as do therapeutic strategies. Mesalazine 
with or without probiotics has failed to prevent diverticulitis recurrence, whereas new studies 
are needed to validate preliminary positive results with rifaximin. Surgery is another option, 
but the number of acute events cannot guide this indication. We need to identify risk factors 
and disease progression or recurrence mechanisms to implement appropriate preventive 
strategies.
Keywords: antibiotics, diverticular disease, diverticulitis, fiber, mesalazine, probiotics, 
rifaximin, treatment
Received: 21 April 2018; accepted in revised form: 11 June 2018.
Correspondence to:  
Angel Lanas  
Servicio de Aparato 
Digestivo, Hospital Clínico 
Universitario Lozano 
Blesa, C/ San Juan Bosco 
15, Zaragoza, 50009, Spain. 




Servicio de Aparato 
Digestivo University Clinic 
Hospital Lozano Blesa, 
Spain
789055 TAG0010.1177/1756284818789055Therapeutic Advances in GastroenterologyA Lanas, D Abad-Baroja
review-article20182018
Review
Therapeutic Advances in Gastroenterology 11
2 journals.sagepub.com/home/tag
cases of diverticular disease in 2000 to more than 
70,000 in 2006,5 and cases with complicated dis-
ease almost doubled between 1990 and 2005.6
US data from 2010 showed that diverticular dis-
ease was the eighth most frequent outpatient gas-
trointestinal diagnosis7 and that there were over 
216,000 cases of AD without hemorrhage admis-
sions in 2012, a 21% increase compared with 
2003.7 In the same report, diverticular hemor-
rhage, included in the gastrointestinal hemor-
rhage diagnosis, was the most frequent diagnosis 
of admission, with over 500,000 cases in 2012. 
Finally, when all causes of death for gastrointesti-
nal, liver, and pancreatic diseases in the USA are 
considered, diverticular disease ranked 16th in 
2012, with a crude rate of 0.9 per 100,000 
patients.
Approximately two thirds of adults will develop 
DDC.8 From an epidemiological point of view, 
the two dominant characteristics of this condi-
tion when considering both prevalence and inci-
dence are the geographical- and age-dependent 
differences in the populations studied. In west-
ern and industrialized countries, DDC is largely 
age dependent and uncommon in young people, 
with a prevalence of 5% in those under age 40 
years, increasing up to 65% in those aged 65 
years or more. The classic observation holds 
that the disorder has the highest prevalence 
rates in these areas but is rare in rural areas of 
nonindustrialized countries.9 One widely 
accepted explanation for this geographic varia-
tion is that the fiber-poor diet consumed in 
western countries plays a decisive etiological 
role. In fact, a change in immigrant diets to 
western diets has been proposed to have shifted 
the prevalence patterns in those populations10 
(Figure 1). Results of several studies support 
this hypothesis, suggesting an increased number 
of total diverticulosis cases and increasing rates 
of diverticular disease–related hospitalizations 
in these populations compared with rates in 
their countries of origin.10,11 Recent reports 
from nonwestern countries also show a greater 
and growing prevalence of diverticulosis in these 
areas than previously appreciated.12–16
Geography has emerged as an additional deter-
minant of where diverticula arise within the 
colon. In western countries, a left-sided predom-
inance of DDC has been described, with approx-
imately 90% of patients having diverticulosis in 
this region. In contrast, individuals from Asian 
countries tend to have a 75–85% right-sided pre-
dominance of diverticulosis.17 However, emerg-
ing data suggest that right-sided diverticulosis in 
Western countries has been underestimated, 
with some described rates between 20% and 33% 
of cases.18 Beyond geography, ethnicity or 
race do not seem to be factors. No difference in 
the prevalence of diverticulosis among black and 
white populations has been observed, although 
Figure 1. Graphical expression of relative risks (RRs) and 95% confidence of intervals (CIs) of 
sociodemographic determinants of hospital admissions for diverticular disease adjusted for the year of birth 
and sex. Reference for ethnicity was native Swedish people. The figure depicts 10-year risk of hospitalization 
due to diverticular disease observed in a cohort of 4 million residents in Sweden. It shows lower risk in 
nonwestern immigrants compared with native Swedish people. Determinants other than ethnicity can be found 
in the study by Herne and colleagues10 and include type of work, recipient of social welfare, type of housing 
and urban residency.
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the distribution of diverticula differs by race, 
with black people having a greater percentage of 
diverticula in the proximal colon compared with 
white people.19,20
At some point in their disease course, an esti-
mated 5–25% of patients with colonic diverticu-
losis will suffer an episode of AD and up to a third 
may experience complications.1 Data from the 
English Health Care System indicate that 16.3% 
of inpatient admissions related to diverticular dis-
ease eventually involve surgery, of which 58.1% 
are emergency surgeries and 41.9% elective. The 
overall surgical admission mortality rates are 
10.1% and 15.5% at 30 days and 1 year, respec-
tively (mortality rates, 2.1% and 5.3% at 30 days 
and 1 year for elective surgery; 15.9% and 22.8% 
at 30 days and 1 year with emergency surgery), 
and overall inpatient admissions mortality rates 
are 5.1% and 14.5% at 30 days and 1 year, respec-
tively. In addition, the overall 28-day readmission 
rate is 9.6%.5
Pathogenic mechanisms in DDC that 
determine current therapeutic approaches
The pathogenic mechanisms involved in DDC 
are complex and not completely understood. 
Below, we describe some mechanisms that have 
been reported and underlie some therapeutic 
approaches currently used in the management of 
DDC.
Colonic wall structure
The colonic wall that holds diverticula shows a 
thickening attributed to elastin deposition within 
the muscle fibers with a greater than 200% 
increase in elastin deposition between the muscle 
cells in the taenia compared with controls.21,22 
An increase in type III collagen synthesis in 
patients with diverticulosis has been described, 
raising the possibility that age-related changes in 
collagen composition are also an etiological 
factor.21 Moreover, overexpression of a tissue 
inhibitor of metalloproteinases, which regulate 
deposition of extracellular matrix proteins, and 
an increase in levels of this molecule have been 
described in the colonic tissue of these patients, 
which might explain the increase in elastin and 
collagen deposition in the colonic wall with diver-
ticular disease.23,24 These data are consonant 
with the higher rate of diverticulosis reported in 
patients with connective tissue disorders.2
Motility
Early investigations demonstrated higher resting, 
postprandial, and neostigmine-stimulated lumi-
nal pressures in patients with diverticulosis com-
pared with controls.25,26 These findings 
encouraged a hypothesis based on segmentation 
of the colon, postulating that contraction of the 
colon at the haustral folds causes the colon to act 
not as a continuous tube but as a segmented 
organ subjected to high pressures.27,28 Classically, 
it has been suggested that the western diet, with 
its deficiency in fiber, may facilitate augmented 
hypersegmentation, increasing the tendency to 
form diverticula. The abnormal pressures and 
tonicity may contribute to both formation of 
diverticula and bowel dysfunction in patients with 
diverticulosis. In addition, patients with sympto-
matic diverticular disease have higher motility 
indices than either asymptomatic patients or con-
trols without colonic diverticuli.29 Moreover, ret-
ropropagation of contractile waves in diverticular 
segments of colon has been documented, indicat-
ing that motility in these patients may be abnor-
mal in both magnitude and direction.30 Finally, a 
lower number of interstitial cells of Cajal has been 
reported in the colonic wall of patients with diver-
ticuli, which may be involved in alterations of the 
intestinal motility.31 An increased activity of 
excitatory cholinergic nerves and decreased activ-
ity of nonadrenergic, noncholinergic inhibitory 
nerves both appear to induce imbalance in the 
normal excitatory and inhibitory influences, 
which results in increased tonicity.32
Environmental factors
Dietary habits involving low fiber content and high 
red meat intake,33–38 obesity,39,40 smoking,25,26,41 
physical inactivity,42–44 alcohol,45,46 and nonsteroi-
dal anti-inflammatory drugs (NSAIDs)47 have 
been reported as risk factors for DDC (Figure 2).
Heritable factors
A Danish study found that diverticulosis and its 
complications aggregate strongly in families, with 
a threefold increased probability of DDC among 
siblings of index cases than the general popula-
tion.48 Another recent investigation reported an 
odds ratio (OR) of 7.15 [95% confidence interval 
(CI) 4.82–10.61] for developing diverticular dis-
ease if a monozygotic twin is affected, and esti-
mated the hereditable component of diverticular 
disease at approximately 40%.49 A single nuclear 
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polymorphism in the TFNSF15 gene has been 
considered a marker of complicated diverticulitis, 
suggesting a key role of T-cell receptor gene in 
T-cell maturation.50 More recently, a rare single 
nucleotide variant in the laminin-β 4 gene 
(LAMB4) has been associated with early onset 
diverticulitis and unrelated nonfamilial sporadic 
diverticulitis.51
Microbiota alterations
The rapid growth of studies focused on the intes-
tinal microbiome has also been a topic of interest 
in the context of DDC, which may be a clear ther-
apeutic target. Disease-specific variations in 
intestinal microbiome composition have been 
found for a number of intestinal disorders. In a 
recent study, fecal microbiota was compared 
among diverticulitis patients and control partici-
pants, with findings that Firmicutes/Bacteroidetes 
ratios and Proteobacteria load were comparable 
among these groups, but that microbiota diversity 
was higher in diverticulitis for Proteobacteria and 
all phyla.52 Another recent cross-sectional study 
found that patients with diverticula have an 
increase in colonic macrophages and a depletion 
of Clostridium cluster IV.53 Clostridium cluster IX, 
Fusobacterium, and Lactobacillaceae are reduced 
in symptomatic diverticular disease compared 
with people without symptoms and diverticuli 
confirmed by colonoscopy. Six urinary metabo-
lome molecules allow discrimination of diverticu-
lar disease and control groups with over 95% 
accuracy.53 Small intestinal bacterial overgrowth, 
commonly known as SIBO, is a frequent and 
easily diagnosed form of intestinal dysbiosis. 
SIBO has been reported to be present in sympto-
matic uncomplicated diverticular disease 
(SUDD)54 and uncomplicated AD,55 which may 
contribute to generate and perpetuate the symp-
toms. Gatta and Scarpignato have shown56 in a 
meta-analysis that rifaximin, one of the drugs 
used in the treatment of DDC, is effective and 
safe in the treatment of SIBO.
However, although these data are all encouraging 
and suggest the presence of dysbiosis in patients 
with diverticular disease, evidence is still insuffi-
cient to ensure that microbiota alterations may be 
behind the development or progression of colonic 
diverticular disease.
Inflammation
In recent years, several findings have supported a 
significant role of low-grade inflammation in 
patients with symptomatic uncomplicated and 
the development of complicated diverticulosis.57,58 
Evidence highlighted as supporting this hypothe-
sis includes enhanced expression of proinflamma-
tory cytokines such as tumor necrosis factor 
(TNF)-α, which decreases with treatment,59–61 
and the fact that obesity is a risk factor for diver-
ticulitis recurrence because of a proinflammatory 
effect of adipokines and chemokines.62 Persistent 
endoscopic and histological inflammation has 
also been reported and identified as a significant 
risk factor for diverticulitis recurrence.63 A recent 
study found that compared with controls, patients 
with diverticula, regardless of symptoms, had a 
Figure 2. Risk of hospital admission or death due to diverticular disease associated with diet habits in a 
cohort of 47,033 men and women living in England and Scotland. In relative terms, that risk was 31% lower 
for vegetarian or vegan patients compared with meat eaters. The risk was 41% lower for those patients taking 
fiber in the highest fifth quintile.39. CI, confidence interval; RR, relative risk.
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greater than 70% increase in colonic mac-
rophages. However, this low-grade inflammation 
hypothesis has recently been challenged. In a pro-
spective study, Peery and colleagues64 analyzed 
619 patients undergoing a screening colonoscopy, 
255 of whom (41%) had colonic diverticula. 
These authors found no association between 
diverticulosis and TNF (OR 0.85; 95% CI 0.63–
1.16), and no association with CD4+, CD8+, or 
CD57+ cells. Compared with controls without 
diverticulosis, biopsy specimens from individuals 
with diverticulosis were less likely to express the 
inflammatory cytokine interleukin 6, and no asso-
ciation or evidence for inflammation was found in 
symptomatic patients when those with versus 
without diverticulosis were compared. Similar 
conclusions were reported in another study with a 
smaller sample size.65
Clinical presentation of DDC and therapeutic 
management
Most patients with colonic diverticula have no 
symptoms; however, it has been estimated that 
20% of patients with diverticulosis develop symp-
toms such as abdominal pain, malaise, swelling, 
and alteration of bowel habits, which are often 
difficult to differentiate from functional disorders 
such as irritable bowel syndrome.1 A recent report 
outlines the main features that could help differ-
entiate the conditions (Table 1).
Symptomatic DDC includes a broad spectrum of 
clinical manifestations and entities, ranging from 
symptomatic diverticular disease without complica-
tions to patients with diverticula who present with 
segmental colitis, colonic diverticular hemorrhage, 
and AD. Very often, symptoms are recurrent (in all 
their spectrum of clinical conditions) and alternate 
with periods of apparent clinical silence. Several 
studies have concluded that even mild sympto-
matic DDC has a negative impact and affects qual-
ity of life compared with control populations.66,67 
This impact has recently been validated in a new 
test (DV-QoL) designed specifically to assess the 
quality of life in patients with diverticular disease, 
showing a broad spectrum of negative psychologi-
cal, social, and physical effects in these patients.68 
In a recent study, Carabotti and colleagues ana-
lyzed QoL scores in an Italian cohort of 1217 
patients with diverticulosis. They found signifi-
cantly higher physical and mental component 
scores in asymptomatic patients with diverticulosis 
in comparison to patients with SUDD or patients 
who had a previous episode of diverticulitis. No dif-
ferences were found between these last two groups, 
which reinforces the negative impact of this entity 
on the quality of life of patients.69
Overall, the goals of treatment of the different 
forms of diverticular disease are focused on allevi-
ating symptoms and preventing progression, 
major complications, and recurrence.70
Asymptomatic DDC
Asymptomatic diverticulosis is usually an inci-
dental finding in patients who undergo colonos-
copy or image techniques for other indications. It 
should be noted that diverticulosis is the most 
common abnormality on colonoscopy.3 There is 
no clear indication for any specific therapy or spe-
cial follow up in patients with asymptomatic 
diverticulosis, and no treatment is required. One 
Table 1. Clinical and biochemical characteristics for the differential diagnosis between SUDD and IBS.
Clinical characteristic and 
biochemical parameter
SUDD IBS
Abdominal pain Yes Yes
  Diffuse No Yes
  Left lower quadrant Yes No
  Lasts for > 24 h Yes No
Relief after bowel movement No Yes
Increased fecal calprotectin Yes No
IBS, irritable bowel disease; SUDD, symptomatic uncomplicated diverticular disease.
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study found no association between constipation, 
low-fiber diet, and the presence of colonic 
diverticulosis.71 However, prevention of progres-
sion of DDC to symptomatic DD is a therapeutic 
target, and several guidelines include specific rec-
ommendations.72–77 Because only a minority of 
patients with DDC develop symptoms or pro-
gress to more severe forms of the disease, it would 
be of interest to detect the susceptible population. 
Today, no studies are available that could gener-
ate personalized recommendations for people 
with asymptomatic DDC, but genetic studies or 
better longitudinal analysis of the microbiome of 
people who eventually develop symptomatic 
DDC should be conducted. At present, only a 
few cross-sectional epidemiological studies have 
analyzed the microbiome of patients with DDC. 
As commented above, Barbara and colleagues53 
reported that the fecal microbiota of patients 
with colonic diverticulosis show differences in 
symptomatic versus asymptomatic patients. Using 
mucosal biopsies from the sigmoid colon of 
226 patients with and 309 without diverticula 
during first-time screening colonoscopy, Jones 
and colleagues78 found few differences among 
cases and controls and only very weak associa-
tions for comparisons of bacterial abundances in 
phylum Proteobacteria (p = 0.038) and family 
Comamonadaceae (p = 0.035). They concluded 
that the mucosal adherent microbiota community 
composition was unlikely to play a substantial 
role in the development of diverticulosis. Tursi 
and colleagues79 assessed fecal microbiota from 
15 patients with SUDD, 13 with asymptomatic 
diverticulosis, and 16 healthy controls. Their 
results also showed that the overall bacterial 
abundance of dominant species did not differ 
among the groups, and again only small differ-
ences (e.g. higher amount of Akkermansia mucin-
iphila species in patients bearing diverticula 
compared with controls) of unclear significance 
were detected.79
Current recommendations (Table 2) for this 
stage of the disease are nonspecific and unse-
lected for all people and include dietary recom-
mendations, such as a classically high-fiber diet. 
However, scientific evidence that supports this 
recommendation for the sole purpose of prevent-
ing symptoms is lacking, although it might be 
considered part of lifestyle changes that could 
offer other health benefits, such as smoking cessa-
tion, avoiding alcohol consumption, and regularly 
exercising.72–77 Quality of evidence is rated as low, 
but a large cohort of 47,033 patients without a 
history of previous diverticulitis reported a 31% 
reduction in risk for incident hospitalization for 
diverticular disease in patients with a high-fiber 
diet (Figure 1).38 Evidence is lacking to support 
claims that a diet rich in nuts, popcorn, or seeds 
has a beneficial or a harmful effect, so these 
foods should not be categorically avoided or 
recommended.80
Other measures suggested at this stage also 
encourage primary prevention and treatment of 
diabetes mellitus, which has been associated with 
a higher risk for symptomatic and complicated 
diverticular disease and colonic diverticular hem-
orrhage.81 Low levels of vitamin D, obesity and 
smoking should be avoided to prevent progres-
sion to symptomatic DDC and AD.82,83
Symptomatic uncomplicated diverticular 
disease
SUDD is defined by the presence of nonspecific 
attacks of abdominal pain of a diverticular source 
without evidence of an inflammatory process and 
alteration in bowel habits. Pain is typically colic-
like in nature, but can be constant, and is often 
relieved by passing flatus or with defecation. 
Other symptoms are diarrhea, constipation, 
bloating, and tenderness in the left lower quad-
rant or changes in bowel habits.1 This entity 
shares clinical similarities with irritable bowel 
syndrome, so it is sometimes difficult to distin-
guish them or attribute the symptoms to the pres-
ence of diverticula (see Table 1). Moreover, 
irritable bowel syndrome is 4.7-fold more likely in 
patients after an episode of AD than in controls, 
complicating the diagnosis even more.84 
Laboratory diagnostic evaluation should be nor-
mal in patients with SUDD, but some data sug-
gest that fecal calprotectin levels are higher in 
patients with SUDD compared with normal con-
trols and patients with irritable bowel syndrome.85 
These data need further confirmation because 
this biomarker might represent a way to differen-
tiate the conditions.
Figure 3 depicts current treatment options for 
this condition and the pathogenic basis underly-
ing these options. Use of fiber has been a main-
stay of SUDD treatment despite a weak evidence 
base for this practice. In addition, the literature 
offers no strong guidance regarding type, (e.g. 
soluble fiber which mainly bulks stool by drawing 
A Lanas, D Abad-Baroja et al.
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fluid/water into stool residues, or insoluble fiber 
which increases bacterial fermentation and accel-
erates colonic transit time, as well as increasing 
biomass and inducing changes in colonic pH and 
intestinal microbiome)86 and quantity of fiber 
needed, although in SUDD the insoluble fibers 
can sometimes worsen symptoms by increasing 
bloating and flatulence, as happens in irritable 
bowel syndrome.87,88
Data on the use of fiber as a unique treatment for 
SUDD are ambiguous, but fiber is still recom-
mended,72–77 complemented by other compounds 
such as cyclic rifaximin (400 mg/12 h for 7 days 
per month), a combination that is 29% more 
effective than placebo for symptom relief at 1 
year; the number needed to treat for this benefit 
was 3.72–77 Based on three open and two double-
blind randomized clinical trials, one systematic 
review, and two meta-analyses, the Italian 
Consensus conference73 concluded that fiber plus 
rifaximin leads more patients to be symptom free 
compared with fiber alone and that rifaximin plus 
fiber is more effective than fiber alone in prevent-
ing AD, with a low therapeutic advantage.
The use of rifaximin is based on the hypothesis 
that disturbances in the intestinal microbiota might 
predispose patients to inflammation and excessive 
production of intestinal gas that eventually induces 
symptoms.1,90 Rifaximin is a nonabsorbable antibi-
otic with broad-spectrum activity that decreases 
the metabolic activity of intestinal flora, increases 
fecal mass, and reduces bacterial overgrowth. Its 
safety and tolerability are high because of its very 
low absorption rates, which implies that nonen-
teric pathogens are not exposed to selective pres-
sure and the risk of bacterial resistance.70
Based on the hypothesis that diverticular disease 
may reflect a dysbiosis (see above), probiotics are 
also being studied in SUDD, although evidence is 
lacking to support their use routinely and guide-
lines do not currently recommend then.72–77 
Modification of the microbiome combining rifax-
imin and probiotics in the long term may be worth 
exploring as a target.
Additional medical therapies for SUDD, such as 
mesalazine, are controversial. Mesalazine was 
suggested as potentially effective in the treatment 
Table 2. Overall treatment recommendations in DDC.









Regularize vitamin D levels
Prevent/treat diabetes
In general these 
recommendations are 
associated with reduced risk 
of hospitalizations
No impact of diet with nuts, 
popcorn, fine grains
SUDD Cyclic rifaximin  
(400 mg/12 h) 7 days/month
High-fiber diet ± 
supplemental fiber
Continuous mesalazine (?) 
(800 mg/12 h)*
Cyclic rifaximin
High-fiber diet ± 
supplemental fiber
Continuous mesalazine (?) 
(800 mg/12 h)*
No evidence for probiotics 





Mesalazine (800 mg/12 h) No long-term treatment 
recommended
Poor evidence







Surgery should not be guided 
by the number of episodes
*Mesalazine was found to be effective in just one a meta-analysis.
$One proof of concept study.
DDC, diverticular disease of the colon; NSAID, nonsteroidal anti-inflammatory drug; SUDD, symptomatic uncomplicated diverticular disease.
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of SUDD in a way similar to its effects on inflam-
matory bowel disease, based on the pathogenic 
hypothesis that a low-grade level of inflammation 
is present in the colonic mucosa of patients with 
SUDD. Only the Polish guidelines suggest that 
mesalazine can be used long term in SUDD.72 
However, available individual studies do not con-
firm that this approach with mesalazine is effective 
in the treatment of SUDD or in diverticulitis pre-
vention.73–77 A recent meta-analysis did show that 
mesalazine administration achieves symptomatic 
relief and reduces diverticulitis occurrence in a 
larger proportion of patients with SUDD. However, 
the absolute risk reduction was statistically signifi-
cant only when mesalazine was compared with pla-
cebo, a high-fiber diet and low-dose rifaximin.89 
Mesalazine seems to be effective in preventing 
diverticulitis occurrence from SUDD, but not in 
preventing secondary diverticulitis recurrence. The 
difference between these entities could be because 
SUDD can be linked to mucosal inflammation, 
whereas AD is characterized by transmural inflam-
mation, leading to fibrosis, which may be the key 
feature explaining mesalazine effectiveness in 
SUDD but not in diverticulitis.89
Finally, anticholinergic and antispasmodic agents 
have been tested concerning the pathogenic presence 
of hypermotility of the colon in patients with diver-
ticulosis; however, there is no adequate evidence 
documenting a benefit.72–77
Segmental colitis associated with diverticulosis
Segmental colitis associated with diverticulosis 
(SCAD) is a recent entity recognized as a distinct 
and poorly understood manifestation of divertic-
ular disease. It is defined as a segmentary chronic 
inflammation of the colon in patients with diver-
ticulosis that can mimic the clinical presentation, 
endoscopic findings, and histologic findings of 
inflammatory bowel disease, being in some cases 
indistinguishable from it.91 The prevalence of 
SCAD in patients with diverticulosis has been 
described as 0.3–1.3%.92 This diagnosis requires 
the exclusion of inflammation in the rectum and 
other areas of the colon through biopsies to dif-
ferentiate it from inflammatory bowel disease.73 
Evidence is insufficient to recommend correct 
management of this entity, although mesalazine 
has been suggested, based on its pathophysiol-
ogy. In any case, the distinction between SCAD 
and inflammatory bowel disease is important 
because their natural history and prognosis dif-
fer: no long-term medications are required for 
SCAD.93,94
Figure 3. Algorithm defining current therapeutic strategies for symptomatic uncomplicated diverticular 
disease (SUDD). Evidence is very poor, supporting the use of fiber or spasmolitics. Evidence is also limited 
for the use of other compounds, but rifaximin has been shown to reduce symptoms and reduces the risk of 
development of acute diverticulitis, whereas mesalazine use is controversial, since it was found not to relive 
symptoms or prevent acute diverticulitis in some studies, although a recent meta-analysis shows that it can be 
effective for both outcomes.72–77,89
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Acute diverticulitis
Uncomplicated versus complicated diverticulitis. 
Colonic AD is a worldwide health problem, as 
one of the most common diagnoses in emergency 
rooms, and the leading cause for elective colonic 
resection.8,95–97 Approximately 5–25% of patients 
with colonic diverticulosis will develop an epi-
sode of AD; 85% of those episodes will be 
uncomplicated,98 One 11-year follow-up study of 
incidental diverticulosis during a colonoscopy 
performed for other reasons found that 4.3% 
eventually develop an episode of AD at a rate of 6 
per 1000 patient years. The incidence rate was 
only 1.5 per 1000 patients when using a rigorous 
definition of diverticulitis confirmed by a con-
trast-enhanced computed tomography (CT) 
scan or surgery.99 A recent analysis of the tempo-
ral trends of the diagnosis of AD showed a 50% 
increased incidence of diverticulitis in 2000–
2007 (188/1000 person years) compared with 
1980–1989 (115/100,000 person years), with an 
especially relevant increase in women and in 
younger people.100 Complicated AD includes the 
development of intra-abdominal peritoneal infec-
tion and perforation. Hinchey’s classification dis-
tinguishing five stages of AD is widely used 
globally (Table 3).101
Classic symptoms of AD involve fever, left lower 
abdominal pain, tenderness, and leukocytosis, 
among other signs.102 These clinical symptoms 
are suggestive of AD, but a definitive diagnosis is 
confirmed by ultrasonography or, even better, a 
contrast-enhanced CT scan.102 Ultrasounds are 
often used as a first-line diagnostic tool in 
patients with suspected AD, and with an expert 
radiologist, it can be conclusive, leaving CT 
scans only for doubtful cases. Following this 
strategy could reduce the number of CT exams 
by about 50%.103
The reason some people develop AD and others 
do not is not well understood. Several studies 
have identified some risk factors for AD, which 
include physical inactivity, obesity, constipation, 
smoking, and use of aspirin or NSAIDs.98 Statin 
use was reported to be protective against AD epi-
sodes, but this finding was not confirmed in a 
recent study.104 A genetic predisposition has been 
indicated, but the clinical significance of these 
studies is questionable.49 Accurate predictors of 
progression to complicated AD are not available. 
Leukocytosis with neutrophil count, white cell to 
lymphocyte ratio,105 procalcitonin levels106 or 
higher levels of calprotectin have been linked to 
severe AD.107
Recurrence of AD is common and occurs in 15–
30% of cases after a first episode of AD.98 
Treatment goals in AD include reduction or alle-
viation of symptoms and inflammation, along 
with prevention of complications and recurrence 
(Figure 4).
Treatment of uncomplicated AD (Hinchey stage 0 
or Ia). Inpatient versus outpatient treatment and 
antibiotics versus no antibiotics for uncomplicated 
AD A conservative strategy with broad-spectrum 
antibiotics for at least 7 days in uncomplicated 
AD can resolve up to 70–100% of events.108 In 
recent years, outpatient management in these 
cases has become more frequent, saving costs to 
health systems.109 However, outpatient treatment 
should not be considered among patients over 
age 80–85 years or those with severe comorbidi-
ties, oral intolerance, or immunosuppression. A 
short hospital stay can be enough.4,95
Two prospective randomized clinical trials sup-
port outpatient management.110,111 In the first 
trial, almost all patients benefited from outpatient 
Table 3. Hinchey’s classification.
− Stage 0: clinically mild diverticulitis
− Stage Ia: pericolic inflammation
− Stage Ib: pericolic or mesocolic <5 cm abscess
− Stage II: intra-abdominal, pelvic or retroperitoneal abscess or abscess distant from the primary 
inflammation
− Stage III: generalized purulent peritonitis
− Stage IV: fecal peritonitis
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management with only 6% requiring hospital 
admission. The results showed similar rates of 
complications and relapse between inpatients and 
outpatients, with significant cost savings.110 The 
second trial included 132 patients randomized to 
hospitalization versus outpatient treatment after 
confirmation of left-sided uncomplicated AD by 
CT scan, and treated with antibiotics. Treatment 
failure was not different between groups (four 
versus three patients in each group; p = 0.619).111 
Furthermore, a recent systematic review includ-
ing 11 articles [one randomized controlled trial 
(RCT)] concluded that outpatient management 
for uncomplicated AD had a treatment success 
rate from 91.5% to 100%, with less than 8% of 
patients readmitted to the hospital.112 Although 
outpatient management for patients with uncom-
plicated AD and no comorbidities seems feasible, 
further studies are needed to evaluate short-term 
and long-term recurrence rates to optimize and 
stratify the appropriate patients for this type of 
management.
Another innovative therapeutic approach is being 
suggested and recommended in several studies 
worldwide to reduce the use of antibiotics in the 
clinical management of these uncomplicated 
cases. Antibiotic treatment should be used in 
selected cases such as patients with signs of gen-
eralized infection, immunosuppressed patients, 
or conservative nonantibiotic treatment failure. 
Two systematic reviews have called antibiotic 
usage into question.113,114 The first systematic 
review identified three RCTs and reported that 
antibiotic use did not reduce the duration of 
symptoms or prevent subsequent complications 
or recurrence.113 However, we note that the qual-
ity of evidence from the included trials was low 
because of a high risk of bias, and only patients 
with modified Hinchey stage Ia and Ib were 
included, thus excluding immunocompromised 
patients, those with symptoms of sepsis, or sig-
nificant comorbidity. Data from a RCT by 
Chabok and colleagues found that antibiotics 
may reduce complication risk during treatment 
[relative risk (RR) 0.49; 95% CI 0.12–1.95], but 
with no statistical significance.115 A recent sys-
tematic review including eight studies with over 
2400 patients found no difference in complica-
tion rates between patients taking antibiotics and 
nonantibiotic usage, with only increasing length 
of hospital stay without antibiotics.114 Also, a 
recent multicenter RCT of systemic antibiotic 
treatment (1.2 g of amoxicillin clavulanic acid/6 h 
intravenously for a minimum of 48 h and then 
switched to oral administration of 625 mg/8 h) 
versus observation with no antibiotics for a first 
episode of uncomplicated AD showed that the 
observational arm was not associated with poorer 
outcomes.116
Recommended antibiotic regimens include cipro-
floxacin plus metronidazole, penicillin derivatives 
such as ampicillin or piperacillin/tazobactam, and 
third-generation cephalosporin to cover gram-pos-
itive, gram-negative, and anaerobic bacteria. Data 
do not support intravenous antibiotic treatment 
over oral treatment, and duration of treatment 
from 4 days to over 7 days does not seem to have 
any advantage related to clinical outcomes.111,117,118 
Figure 4. Algorithm defining current therapeutic strategies for acute diverticulitis. See the appropriate section 
in text.
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It should be emphasized, however, that the choice 
of antimicrobials is entirely empiric, since no trial 
has compared the efficacy of the different regimens 
mentioned above.70
Treatment of complicated AD (Hinchey stages Ib 
to IV). Hinchey Ib or II includes pericolic or 
mesocolic (<5 cm) abscess or intra-abdominal, 
pelvic, or retroperitoneal abscess, or abscess dis-
tant from the primary inflammation. Only 15% of 
patients suffering an episode of AD will develop a 
complicated episode with pericolic/distant con-
fined abscess or worse.108 In these cases, inpatient 
management should be indicated, and treatment 
varies with the size of the abscess. Conservative 
treatment with nothing other than a broad-spec-
trum antibiotic has a success rate up to 70% in 
abscesses smaller than 4 cm,119 leaving image-
guided percutaneous drainage for previous treat-
ment failures and larger abscesses with a successful 
treatment rate in up to 80% of cases.120 Surgery 
should be planned when conservative treatment 
fails.
Hinchey III or IV includes generalized purulent 
peritonitis/fecal peritonitis. Data show a mortality 
rate of 14% in patients with complicated Hinchey 
III and IV in AD. In the vast majority of hemody-
namically stable cases, early surgery with primary 
anastomosis with or without fecal diversion is 
preferable when the patient’s clinical condition 
can influence different surgery treatments. 
Hartmann’s surgery procedure is performed in 
hemodynamically unstable patients.108,121
There is debate concerning the best surgical strat-
egy in complicated AD. Laparoscopic surgery 
seemed to offer better outcomes than open sur-
gery in AD in a prospective, multicenter, double-
blind, parallel-arm RCT of 104 patients with 
Hinchey I, IIa, or IIb, symptomatic stricture, or 
severe rectal bleeding. Laparoscopic surgery was 
associated with a 15.4% reduction in major com-
plication rates, less pain, improved quality of life, 
and shorter hospitalization.122 Both the short-
term and long-term results of the Sigma trial 
show a 27% reduction in major morbidity for 
patients undergoing laparoscopic surgery for 
diverticular disease.123 A multicenter, parallel-
group, randomized, open-label trial, however, 
showed no superiority of laparoscopic lavage 
compared with sigmoidectomy in patients with 
purulent perforated diverticulitis.124 In a recent 
case–control study of 1175 patients undergoing 
surgery for Hinchey III or IV peritonitis, preop-
erative assessment based on an Apgar scoring sys-
tem integrated with peritonitis exposure in 
complicated diverticulitis offered the best surgical 
management strategy for reducing local infection, 
complications, and the need for ostomy.125
Prevention of recurrence following an episode 
of AD
After one episode of AD, 15–30% of patients 
will develop a recurrent episode, although a 
recent large population-based cohort study 
reported a lower 11.2% recurrence rate of 
hospital admission,126 lower than previously 
reported,127 which seems greater in women and 
younger people.128 The second episode carries 
another 30% risk of having a third event,4 but 
the first episode seems the most severe.129 
Patients also present often chronic abdominal 
pain after an AD event that may be difficult to 
manage.130 Although quality evidence is still 
insufficient to identify the best preventive treat-
ment, several secondary prevention strategies 
have been suggested and include a high-fiber 
diet, cyclic antibiotic treatment with rifaximin, 
probiotics, mesalazine treatment, and avoiding 
NSAIDs. The role of surgery is discussed below 
(Table 4).
Dietary and lifestyle recommendations. Classi-
cally, physicians implement a high-fiber diet and 
lifestyle recommendations to reduce the risk of 
recurrent AD, but whether these measures 
improve the risk for recurrence remains to be 
confirmed. No studies are available focusing on 
the effect of fiber intake on recurrence risk of AD. 
We identified two systematic reviews including 
three RCTs regarding the effect of fiber intake on 
patients with SUDD. The results showed a signifi-
cant benefit only on pain reduction.143–145 As 
noted above, the EPIC-Oxford study reported a 
31% reduction in risk for incident hospitalization 
for diverticular disease in patients with high-fiber 
diet intake (Figure 2).38 Strate and colleagues, 
using pooled data from this cohort, estimated that 
a high-fiber diet would result in a reduction of 59 
recurrences of AD at 5 years per 1000 patients 
treated (95% CI 27–85).77 Another extended rec-
ommendation is to exclude seeds, popcorn, and 
nuts from the diet in patients with a history of AD 
because these types of food may accumulate, 
traumatize, and obstruct the diverticular lumen. 
Strate and colleagues, in their large, prospective 
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study including 50,000 patients followed for 20 
years with medical questionnaires, found no asso-
ciation of this consumption with an increased risk 
for AD.77
Weight reduction and smoking cessation may 
reduce the risk of recurrent AD.39–41 Although no 
study has evaluated whether physical activity 
decreases the risk for a second episode of AD, a 
large cohort of almost 50,000 men aged 40–75 
years showed that vigorous physical activity would 
decrease risk for a first AD episode by up to 34% 
(RR 0.66; 95% CI 0.51–0.86), whereas no effect 
was seen with no vigorous physical activity.43 
Obviously, this finding cannot be extrapolated to 
prevention of AD recurrence, and regardless, 
many patients having an AD event are older and 
have different comorbidities that make imple-
menting such a recommendation difficult.
Taking into account several clinical and bio-
chemical parameters one study found that 
increased risks of recurrent AD included being a 
younger patient, female, obese, smoker, have 
dyslipidemia, suffer a first event of complicated 
AD or have a Charlson comorbidity score greater 
than 20.126
Nonabsorbable antibiotics. The only antibi-
otic proposed for this condition is rifaximin, 
so far.73 The suggested dose regimen is 400 
mg twice a day over the first week of the 
month. The role of cyclic rifaximin in pre-
venting AD recurrence has been revisited in 
three systematic reviews with inconclusive 
findings of benefit from rifaximin use.145–147 A 
limited proof-of-concept trial including 165 
patients evaluated the effect of 3.5 g fiber 
supplementation with or without rifaximin 
400 mg taken for 1 week per month for 1 year. 
Recurrences occurred in 10.4% of patients 
taking rifaximin plus fiber versus 19.3% of 
patients taking fiber alone. Patients with a 
prior history of diverticulitis diagnosed at 
least 1 year from receiving rifaximin also had 
a lower incidence of recurrence (10% versus 
67%).131 Therefore, although findings are 
promising, more quality data are needed to 
strongly recommend the systematic use of 
cyclic rifaximin for primary and secondary 
prevention of AD. The multicenter interna-
tional ROAD trial, which will compare rifaxi-
min versus placebo in the prevention of 
diverticulitis after a first episode of AD, will 
be the first to address this question (EudraCT 
number: 2017-002708).
Probiotics. Bacterial dysbiosis has been proposed 
as a mechanism involved in the pathogenesis of 
AD, which suggests that selected probiotics could 
Table 4. Therapeutic strategies for the prevention of recurrence of acute diverticulitis.
Therapeutic 
strategy






Vegetarian diet, high-fiber diet, 
vigorous exercise and avoiding 
smoking are associated with less 




Crowe et al.,38 Strate 






Rifaximin + fiber reduced 
recurrence of AD
Proof of concept 
study that requires 
confirmation











Most studies found no positive 
results with mesalazine alone. 
One study found that mesalazine 
+ rifaximin was better than 





Stollman et al.,133 Parente 
et al.,134 Tursi,135 Khan 
et al.,136 Raskin et al.,137 
Kruis et al.,138 Khan 




No effect Very low quality Giaccari et al.,141 Dughera 
et al.,142 Lahner et al.132
AD, acute diverticulitis.
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have a role in recurrence prevention.70 The first 
observational study that suggested a possible role 
of probiotics evaluated the effect of Lactobacillus 
plus rifaximin in 79 patients with post-diverticuli-
tis colonic stenosis. They found that 88% of 
patients remained asymptomatic after 12 months 
of treatment.141 One small trial of 83 patients 
evaluated the effect of a high-fiber diet alone ver-
sus an Escherichia coli and Proteus vulgaris suspen-
sion plus a high-fiber diet for 2 weeks every 
month, within the first 3 months after an event of 
AD. Investigators suggested that probiotic use 
could reduce by 63% the risk for a second AD 
relapse (RR 0.37; 95% CI 0.08–1.81).142 One 
systematic review of 11 studies (four of them on 
complicated AD) evaluated the efficacy of probi-
otics in diverticular disease in terms of symptom 
remission and prevention of AD. A meta-analysis 
on the efficacy of probiotics in diverticular disease 
could not be performed because of the poor qual-
ity of retrieved studies, and the authors concluded 
that further investigation is required to assess sys-
tematic usage.132
Mesalazine/mesalamine. Mesalamine [also 
known as mesalazine or 5-aminosalycylic acid 
(5-ASA)] is a common therapy among patients 
with ulcerative colitis. Because AD is an inflam-
matory process and resolution may still leave a 
low-grade inflammatory status including crypti-
tis, crypt abscesses, and other architectural 
changes, mesalamine has been proposed to 
reproduce its effects in ulcerative colitis to pre-
vent or reduce recurrence of AD disease. Several 
double-blind and open RCTs have assessed the 
role of mesalamine in the prevention of AD 
recurrence. Most of them showed inconclusive 
results compared with placebo.133–140 A recent 
Cochrane review revised the efficacy of mesala-
mine for the prevention of recurrent AD and 
included 1805 patients in seven studies judged 
to have unclear or high risk of bias. The results 
showed no significant difference for mesalamine 
compared with placebo (RR 0.98; 95% CI 0.91–
1.06; p = 0.63).140 In addition, an American 
Gastroenterological Association review on acute 
diverticular disease analyzed six included clini-
cal trials and found that mesalamine probably 
does not reduce recurrence risk and could in fact 
increase the risk of surgery (RR 1.82; 95% CI 
0.47–7.03), suggesting that 5-ASA usage should 
be applied with caution until consistent and 
quality evidence is available.77
NSAID and aspirin treatment. No studies have 
evaluated the effect of NSAIDs or aspirin on 
patients with prior history of AD, but indirect evi-
dence suggests that these drugs increase the risk 
of AD. These indirect conclusions can be drawn 
from data from a long cohort study of 47,000 
patients without a history of AD. The results 
showed that NSAIDs increased the risk of diver-
ticulitis recurrence [adjusted hazard ratio (HR) 
1.72; 95% CI 1.40–2.11] and complicated diver-
ticulitis (adjusted HR 2.55; 95% CI 1.32–4.95).4 
Aspirin usage was also studied and increased the 
risk of AD by up to 20% (adjusted HR 1.2; 95% 
CI 1.05–1.47). These data, however, must be 
considered with caution because aspirin use in 
patients with prior history of cardiovascular 
events must be maintained, regardless of a history 
of AD events.
Surgery. Until a few years ago, guidelines recom-
mended elective surgery after two episodes of acute 
uncomplicated AD or a single episode in young 
adults, immunosuppressed patients, and compli-
cated AD.148–150 However, based on the increased 
risk of morbidity and mortality in elective surgery 
and the fact that recurrent AD is not more serious 
than a first episode, the clinical trend is to choose 
surgery on a case-by-case basis. Physicians should 
individualize treatment, attending to the patient’s 
medical condition, age, and persistent symptom-
atology as well as the number of recurrences and 
their severity.77,108,150 Approximately 10% of 
patients undergoing elective resection can experi-
ence a major surgical complication.122
Recent data show that the natural history of 
recurrent AD might be more benign than a first 
event, with a lower risk of relapse and emer-
gency surgery, and therefore a lower mortality 
risk.151 It has been hypothesized that recurrent 
episodes of AD may protect against perforation 
because of abdominal adhesion formation.151 
The risk of recurrence in patients after a first 
episode of AD treated medically is estimated to 
be less than 20%,151,152 while the risk of recur-
rence after a successful surgical treatment is 
7%,153 with 10% of patients at risk of experienc-
ing a major surgical complication and increased 
mortality in patients over 85 years undergoing 
elective surgery.149,154 Therefore, a systematic 
elective surgery policy after an episode of AD 
does not decrease the risk of further surgery or 
recurrent AD.
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The case-by-case recommendation concerning 
the option of surgery to prevent recurrence of AD 
must rely on objective findings and not on the 
number of episodes alone. In clinical practice, 
CT scans can grade the severity of AD episodes, 
and left-sided AD, over 5 cm of colon involved, 
and retroperitoneal abscesses are predictors of 
recurrence.155 Also, younger age and persistent 
postoperative symptoms are strong predictors.156 
Risk of recurrence might be slightly higher in 
patients younger than 50 years, with a 23% risk at 
5 years of follow up versus 16% in patients aged 
50 or older.77 Despite these data, age alone should 
not be considered exclusively as a determinant for 
elective surgery, and further data are needed to 
fill these gaps. Immunosuppressed patients are at 
higher risk for complicated recurrent AD, with a 
fivefold increased risk of colonic perforation and 
thus emergency surgery.157 However, another 
study showed that immunosuppressed patients 
have a higher mortality rate only with the first epi-
sode of AD. Therefore, at present, no strong rec-
ommendation for elective surgery is possible in 
this group of patients.158
The role of colonoscopy. Based on expert opin-
ion, all international guidelines recommend 
colonoscopy 4–8 weeks following an episode of 
AD for colorectal cancer exclusion. It is esti-
mated that these recommendations would detect 
about 15 colorectal cancers per 1000 patients 
tested and 38 advanced adenomas after an epi-
sode of AD, with 0.8 colonic perforations per 
1000 patients when the colonoscopy is per-
formed within 7 days after the episode.157 Some 
retrospective studies159–165 and a systematic 
review166 have called into question this clinical 
practice. Recent data suggest that the most effec-
tive strategy would be to perform a colonoscopy 
on patients with suspicious malignancy on CT 
or persistent symptoms after an AD episode. 
Unfortunately, no quality data regarding this 
question are available, and more studies are nec-
essary to make a definitive statement. In any 
case, the need for colonoscopy to rule out the 
presence of an underlying colorectal cancer 
raises the question on the potential association 
between diverticular disease and colorectal can-
cer based on common risk factors. Available data 
show no significant increase in colorectal cancer 
after the first year of follow up, with an increased 
risk within the first 12 months after diagnosis 
probably due to surveillance and misclassifica-
tion in the first place.167,168
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